AVTX — Avalo Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1534120 ·
Last close
$7.13
Market Cap
$412.28M
52W High
$24.27
52W Low
$6.53
ADV30
2,622,180
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -23,397,000 -18,945,000 481,430,000 64,988,000 44,884,000
Jun 2026 0 — -31,517,000 -36,358,000 490,783,000 85,382,000 42,123,000
Mar 2026 0 — -20,901,000 -19,630,000 99,885,000 24,988,000 31,565,000
Dec 2025 59,000 59,000 -19,742,000 -13,720,000 116,458,000 15,858,000 33,409,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-68,290,000
Investing CF
$-315,280,000
Financing CF
$426,664,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.92
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-504,510,000
Inventory
—
Receivables
—
ST Investments
$314,894,000
EBIT TTM
$-91,358,000
Pretax Income TTM
$-100,162,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$59,000
EBITDA
$-91,251,000
Free Cash Flow
$-23,271,000
Enterprise Value
$-20,869,978
Total Cash
$400,276,000
Total Debt
$242,000
Shares Out
57,823,083
Trailing EPS
$-2.26
Book Value
$4.49
ROE
-36.3%
ROA
-18.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 59,000 -72,925,000 -78,259,000 116,458,000 33,409,000 83,049,000 -51,458,000
Dec 2024 441,000 -40,871,000 -35,129,000 150,732,000 17,700,000 133,032,000 -49,056,000
Dec 2023 1,924,000 -23,444,000 -31,544,000 20,993,000 13,689,000 7,304,000 -30,680,000
Dec 2022 18,051,000 -37,440,000 -41,658,000 33,367,000 44,282,000 -10,915,000 -26,751,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$12,134,000
NetIncome TTM
$-100,333,000
OpCashFlow TTM
—
Assets (Latest)
$490,783,000
Forward EPS
$-2.58

Max Pain — expiry 2026-12-18

max pain strike: $7.50 · spot: $6.70 · call oi: 8,572 · put oi: 5,662
Expected Move to 2026-12-18: ±$1.55 (23.13%) — implied range $5.15 – $8.25 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OCS Oculis Holding AG $417.01M $7.51 —
PTCHF PureTech Health plc $405.77M $1.65 —
OVID Ovid Therapeutics Inc. $418.98M $2.22 —
CTMX CytomX Therapeutics, Inc. $422.93M $1.94 —
PRTA PROTHENA CORP PUBLIC LTD CO $424.15M $8.26 —

News headlines (Yahoo Finance, 1h cache)

Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
2026-11-11 20:15 · Yahoo
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
2026-11-05 12:00 · Yahoo
Avalo Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 21:00 · Yahoo
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 20:01 · Yahoo
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
2026-09-23 11:00 · Yahoo
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
2026-08-11 09:12 · Yahoo
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-08-06 11:00 · Yahoo
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
2026-07-22 11:00 · Yahoo
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
2026-07-07 11:00 · Yahoo
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
2026-06-30 01:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.